3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
7
Active not recruiting
2
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
18
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
3
Melanoma
3
Brain Neoplasms
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Pancreatic Neoplasms
2
Osteosarcoma
2
Neuroblastoma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Diffuse Intrinsic Pontine Glioma
2
Colorectal Neoplasms
2
Advanced Cancer
2
Urologic Neoplasms
1
Unilateral Breast Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Multiple Myeloma
1
Interventions
Paclitaxel
37
Carboplatin
28
pembrolizumab
19
Surveys and Questionnaires
11
temsirolimus
10
Radiotherapy
10
Cisplatin
10
Doxorubicin
9
Bevacizumab
9
lenvatinib
8
Docetaxel
8
Nivolumab
7
Metformin
7
Gemcitabine
7
Early Intervention, Educational
7
Counseling
7
Sirolimus
6
Radiation
6
Megestrol Acetate
6
Indocyanine Green
6
olaparib
5
Topotecan
5
Therapeutics
5
Psychiatric Rehabilitation
5
Methods
5
Letrozole
5
Ipilimumab
5
Chemotherapy, Adjuvant
5
ridaforolimus
4
Trastuzumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Endometrial Neoplasms
×
abemaciclib
×
Clear all
NCT03339843
2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2
Completed
85 enrolled